View Entire Collection
By Clinical Topic
By State Requirement
Diabetes – Summer 2012
Future of Nursing Initiative
Heart Failure - Fall 2011
Influenza - Winter 2011
Nursing Ethics - Fall 2011
Trauma - Fall 2010
Traumatic Brain Injury - Fall 2010
Fluids & Electrolytes
THURSDAY, June 21 (HealthDay News) -- Obstructive sleep apnea (OSA) is independently associated with diabetic peripheral neuropathy, even after adjustment for potential confounders, according to a study published online June 21 in the American Journal of Respiratory and Critical Care Medicine.
To investigate whether OSA is associated with diabetic peripheral neuropathy, Abd A. Tahrani, M.D., from the University of Birmingham in the United Kingdom, and colleagues conducted a cross-sectional study of 234 adults with type 2 diabetes (mean age, 57 years) from two U.K. hospitals. The Michigan Neuropathy Screening Instrument was used to diagnose peripheral neuropathy. Home-based, multi-channel respiratory monitoring was used to assess OSA (apnea-hypopnea index ≥5 events/hour).
The researchers found that 65 percent of participants had OSA (median apnea-hypopnea index, 7.2), with 40 percent having moderate to severe OSA. Neuropathy prevalence was significantly higher in patients with OSA than those without OSA (60 versus 27 percent). OSA remained independently associated with diabetic neuropathy even after adjustment for potential confounders (odds ratio, 2.82). Nitrotyrosine and lipid peroxide levels were higher in participants with OSA and were associated with the severity of hypoxemia. In participants with OSA, cutaneous microvascular function was impaired.
"Additional prospective and interventional studies are also needed to examine the role of OSA and intermittent hypoxemia in the development and progression of diabetic peripheral neuropathy in patients with both early and advanced diabetes, and to assess the potential impact of continuous positive airway pressure treatment on diabetic peripheral neuropathy," Tahrani said in a statement.
The study was funded by the U.K. Novo Nordisk Research Foundation and Sanofi-Aventis.
Full Text (subscription or payment may be required)
Sign up for our free enewsletters to stay up-to-date in your area of practice - or take a look at an archive of prior issues
Join our CESaver program to earn up to 100 contact hours for only $34.95
Explore a world of online resources
Back to Top